SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Astellas Pharma Inc. (ALPMF) 当前追踪市盈率 (P/E) 为 0.6, 前瞻市盈率为 0.1. 追踪盈利收益率为 169.49%, 前瞻盈利收益率 909.09%.
本页证实的标准:
- VALUE (100/100, 通过) — 市盈率低于市场平均水平 (0.6); 盈利收益率超过债券收益率 (169.49%).
- 前瞻市盈率 0.1 (低于追踪值 0.6) — 分析师预计盈利将增长，这将改善估值。
- 追踪盈利收益率 169.49% — 超过典型债券收益率（约4.3%），使股票相对固定收益更具吸引力。 前瞻收益率改善至 909.09% 随着盈利恢复。
SharesGrow 综合评分： 71/100 其中 4/7 项标准通过。
SharesGrow 7-Criteria Score
✓
价值
100/100
Price-to-Earnings & upside
Proven by this page
✗
健康
33/100
Debt-to-Equity & liquidity
→ Health
估值概览 — ALPMF
估值倍数
P/E (TTM)0.6
前瞻 P/E0.1
PEG 比率0.00
前瞻 PEG0.00
P/B 比率0.00
P/S 比率0.02
EV/EBITDA0.0
每股数据
EPS (TTM)$28.24
前瞻 EPS（预估）$154.44
每股账面价值$0.00
每股营收$1,064.08
每股自由现金流$0.00
收益率与内在价值
盈利收益率169.49%
Forward Earnings Yield909.09%
股息收益率0.00%
P/E Ratio & Earnings Yield
每股收益 (EPS) 历史
| Year |
EPS（稀释） |
营收 |
净利润 |
净利润率 |
| 2016 |
$89.62 |
$1.37T |
$193.69B |
14.1% |
| 2017 |
$103.55 |
$1.31T |
$218.7B |
16.7% |
| 2018 |
$81.02 |
$1.3T |
$164.68B |
12.7% |
| 2019 |
$114.94 |
$1.31T |
$222.27B |
17% |
| 2020 |
$104.08 |
$1.3T |
$195.41B |
15% |
| 2021 |
$64.90 |
$1.25T |
$120.59B |
9.7% |
| 2022 |
$67.05 |
$1.3T |
$124.09B |
9.6% |
| 2023 |
$54.09 |
$1.52T |
$98.71B |
6.5% |
| 2024 |
$9.47 |
$1.6T |
$17.05B |
1.1% |
| 2025 |
$28.24 |
$1.91T |
$50.75B |
2.7% |
